Home / Aduhelm (Drug) / Alzheimer's Disease / Clinical Trials / Drugs (Pharmaceuticals) / Labeling and Labels (Product) / In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

July 08, 2021 Aduhelm (Drug), Alzheimer's Disease, Clinical Trials, Drugs (Pharmaceuticals), Labeling and Labels (Product)

By BY REBECCA ROBBINS AND PAM BELLUCK from NYT Health https://ift.tt/3wpL7KI

No comments

Subscribe to: Post Comments ( Atom )